The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)

Study Name on
ClinicalTrials.gov (link is external)
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
Study Druglumacaftor/ ivacaftor
Type of Study DrugCFTR modulator
Study TitleA Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety 
of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, 
Homozygous for the F508del-CFTR Mutation
Study Phase3
Study SponsorVertex

Link on
clinicaltrials.gov (link is external)

https://clinicaltrials.gov/ct2/show/NCT02514473 (link is external)

Participating ECFS-CTN sitesPlease contact ecfs-ctn@uzleuven.be for most recent sitelist 
Age6 Years to 11 Years